for orders over $200
Exemestane belongs to the class of steroidal aromatase inhibitors and is structurally related to the natural substrate androstenedione. Estrogen is primarily produced by the modification of androgen through aromatase in postmenopausal women and blocking its production is an effective way to control hormone-sensitive breast cancer. Exemestane binds irreversibly to the active site of aromatase and causes its inactivation, sometimes referred to as suicidal inactivation.
Exemestane doesn’t affect adrenal biosynthesis, progestogenic action and estrogenic activity. It slightly raises serum FSH and LH levels. FDA first approved it in 1999 and it was marketed under the brand name Aromasin. At Element Sarms, the option to buy liquid Exemestane is restricted to educational and research purposes.
IUPAC Name:(8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dioneSynonym: 107868-30-4, AromasinMolecular Formula: C20H24O2Molecular Weight: 296.4 g/molCAS Number: 107868-30-4PubChem CID: 60198
Exemestane has been shown to prevent contralateral breast cancer in postmenopausal women. A randomized double-blind placebo-controlled trial was designed to check the efficacy of exemestane in preventing breast cancer. 4560 postmenopausal women who were at high risk of breast cancer were randomly assigned to receive exemestane or placebo. After 35 months, exemestane showed a 65% relative reduction in invasive breast cancer incidence, also lowering overall invasive and noninvasive breast cancer rates (0.35% vs. 0.77%). Adverse events occurred in 88% of the treatment group and 85% of the placebo group, with no significant differences in fractures, cardiovascular events, other cancers, or treatment-related deaths .
In cases of estrogen-dependent breast cancers, blocking estrogen production by removing ovaries can effectively decrease its progression. Tamoxifen decreases the risk of recurrence by 47% when given after surgery for 5 years. Alternative endocrine therapies can be effective in cases of breast cancer relapse even after tamoxifen treatment.
The intergroup exemestane study (IES) was designed to evaluate whether postmenopausal women, after 2-3 years of tamoxifen for breast cancer, would benefit more by switching to exemestane versus continuing tamoxifen. Participants were randomly assigned to switch to exemestane or to continue to receive tamoxifen. After 2.5 years, exemestane showed a 32% risk reduction vs. tamoxifen, with a 4.7% absolute benefit in 3-year disease-free survival. Further, researchers found that contralateral breast cancer occurred in 20 patients in the tamoxifen group and 9 in the exemestane group .
The Tamoxifen Exemestane Adjuvant Multinational (TEAM) Phase 3 trial was conducted to compare the long-term efficacy of exemestane monotherapy as compared to sequential treatment. The findings indicated that both groups had similar disease-free survival after 5 years. The sequential group had more gynecological symptoms, venous thrombosis, and endometrial abnormalities, while the exemestane-only group had more musculoskeletal issues .
Tamoxifen is the standard treatment of care for breast cancer adjuvant therapy in premenopausal women. SOFT and TEXT trial was conducted to examine whether exemestane is effective for premenopausal women with ovarian function suppression. Researchers randomly assigned participants with hormone receptor-positive breast cancer to receive exemestane plus ovarian suppression and tamoxifen plus ovarian suppression for a period of 5 years. The results found that the exemestane significantly reduced recurrence as compared to the tamoxifen group .
Research shows that exemestane has superior efficacy over megestrol acetate for the treatment of advanced-stage breast cancer in postmenopausal women who didn’t respond to tamoxifen .
Increased PI3K/AKT/mTOR signaling is associated with resistance to endocrine-targeted therapies. Based on the results reported in the BOLERO-2 trial, exemestane along with everolimus (inhibitor of mTOR) has been approved for advanced-stage breast cancer patients who previously progressed on nonsteroidal aromatase inhibitors .
Exemestane is an irreversible steroidal aromatase inhibitor primarily used for the treatment of breast cancer in postmenopausal women. It has also been shown to decrease the risk of cancer in premenopausal women. It is an FDA-approved drug for the adjuvant treatment in estrogen receptor-positive early-stage breast cancer and advanced-stage breast cancer in postmenopausal women. Many clinical trials are ongoing to explore its efficacy in combination with other drugs for HR-positive and HER2-negative premenopausal breast cancer patients. At Element Sarms, Aromasin for sale is solely available for research and educational purchases. Only buy exemestane for approved research.
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind.
The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.